BioCryst Pharmaceuticals, Inc. (BCRX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jon P. Stonehouse | CEO, President & Executive Director | 1.23M | 647.14k | 1961 |
| Mr. Anthony J. Doyle | Senior VP, CFO & Interim Principal Accounting Officer | 845.93k | -- | 1980 |
| Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 794.75k | -- | 1966 |
| Dr. Helen M. Thackray FAAP, M.D. | Chief Research & Development Officer | 976.15k | -- | 1968 |
| Mr. Charles K. Gayer | Senior VP & Chief Commercial Officer | 794.12k | -- | 1971 |
| Mr. John D. Bluth | Chief Communications Officer | -- | -- | 1973 |
| Ms. Stephanie Angelini | Chief People Officer | -- | -- | -- |
| Dr. William P. Sheridan MBBS | Chief Development Officer | 784.09k | 4.4M | 1955 |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer | 691.45k | 1.25M | 1953 |
| Ms. Jinky Ang Rosselli | Chief Data & Insights Officer | -- | -- | -- |
BioCryst Pharmaceuticals, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 536
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Corporate Governance
Upcoming Events
October 31, 2024 at 12:30 PM UTC - November 4, 2024 at 12:30 PM UTC
BioCryst Pharmaceuticals, Inc. Earnings Date